Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Dirven, L, Musoro, JZ, Coens, C, Reijneveld, JC, Taphoorn, MJB, Boele, FW, Groenvold, M, van den Bent, MJ, Stupp, R, Velikova, G, Cocks, K, Sprangers, MAG, King, MT, Flechtner, H-H & Bottomley, A 2021, 'Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients', Neuro-Oncology, vol. 23, no. 8, pp. 1327-1336. https://doi.org/10.1093/neuonc/noab037

APA

Dirven, L., Musoro, J. Z., Coens, C., Reijneveld, J. C., Taphoorn, M. J. B., Boele, F. W., Groenvold, M., van den Bent, M. J., Stupp, R., Velikova, G., Cocks, K., Sprangers, M. A. G., King, M. T., Flechtner, H-H., & Bottomley, A. (2021). Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology, 23(8), 1327-1336. https://doi.org/10.1093/neuonc/noab037

CBE

Dirven L, Musoro JZ, Coens C, Reijneveld JC, Taphoorn MJB, Boele FW, Groenvold M, van den Bent MJ, Stupp R, Velikova G, Cocks K, Sprangers MAG, King MT, Flechtner H-H, Bottomley A. 2021. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology. 23(8):1327-1336. https://doi.org/10.1093/neuonc/noab037

MLA

Vancouver

Dirven L, Musoro JZ, Coens C, Reijneveld JC, Taphoorn MJB, Boele FW et al. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology. 2021 Aug 2;23(8):1327-1336. https://doi.org/10.1093/neuonc/noab037

Author

Dirven, Linda ; Musoro, Jammbe Z ; Coens, Corneel ; Reijneveld, Jaap C ; Taphoorn, Martin J B ; Boele, Florien W ; Groenvold, Mogens ; van den Bent, Martin J ; Stupp, Roger ; Velikova, Galina ; Cocks, Kim ; Sprangers, Mirjam A G ; King, Madeleine T ; Flechtner, Hans-Henning ; Bottomley, Andrew. / Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. In: Neuro-Oncology. 2021 ; Vol. 23, No. 8. pp. 1327-1336.

Bibtex

@article{e9d1e27187734f179ba1d92717998161,
title = "Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients",
abstract = "BACKGROUND: Minimally important differences (MIDs) allow interpretation of the clinical relevance of health-related quality of life (HRQOL) results. This study aimed to estimate MIDs for all European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) scales for interpreting group-level results in brain tumor patients.METHODS: Clinical and HRQOL data from three glioma trials were used. Clinical anchors were selected for each EORTC QLQ-C30 scale, based on correlation (>0.30) and clinical plausibility of association. Changes in both HRQOL and the anchors were calculated, and for each scale and time period, patients were categorized into one of the three clinical change groups: deteriorated by one anchor category, no change, or improved by one anchor category. Mean change method and linear regression were applied to estimate MIDs for interpreting within-group change and between-group differences in change over time, respectively. Distribution-based methods were applied to generate supportive evidence.RESULTS: A total of 1687 patients were enrolled in the three trials. The retained anchors were performance status and eight Common Terminology Criteria for Adverse Events (CTCAE) scales. MIDs for interpreting within-group change ranged from 4 to 12 points for improvement and -4 to -14 points for deterioration. MIDs for between-group difference in change ranged from 4 to 9 for improvement and -4 to -16 for deterioration. Most anchor-based MIDs were closest to the 0.3 SD distribution-based estimates (range: 3-10).CONCLUSIONS: MIDs for the EORTC QLQ-C30 scales generally ranged between 4 and 11 points for both within-group mean change and between-group mean difference in change. These results can be used to interpret QLQ-C30 results from glioma trials.",
keywords = "Brain Neoplasms, Glioma, Humans, Quality of Life, Research Design, Surveys and Questionnaires, minimally important difference (MID), brain tumor, clinical relevance, EORTC QLQ-C30, health-related quality of life (HRQOL)",
author = "Linda Dirven and Musoro, {Jammbe Z} and Corneel Coens and Reijneveld, {Jaap C} and Taphoorn, {Martin J B} and Boele, {Florien W} and Mogens Groenvold and {van den Bent}, {Martin J} and Roger Stupp and Galina Velikova and Kim Cocks and Sprangers, {Mirjam A G} and King, {Madeleine T} and Hans-Henning Flechtner and Andrew Bottomley",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.",
year = "2021",
month = aug,
day = "2",
doi = "10.1093/neuonc/noab037",
language = "English",
volume = "23",
pages = "1327--1336",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "8",

}

RIS

TY - JOUR

T1 - Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients

AU - Dirven, Linda

AU - Musoro, Jammbe Z

AU - Coens, Corneel

AU - Reijneveld, Jaap C

AU - Taphoorn, Martin J B

AU - Boele, Florien W

AU - Groenvold, Mogens

AU - van den Bent, Martin J

AU - Stupp, Roger

AU - Velikova, Galina

AU - Cocks, Kim

AU - Sprangers, Mirjam A G

AU - King, Madeleine T

AU - Flechtner, Hans-Henning

AU - Bottomley, Andrew

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

PY - 2021/8/2

Y1 - 2021/8/2

N2 - BACKGROUND: Minimally important differences (MIDs) allow interpretation of the clinical relevance of health-related quality of life (HRQOL) results. This study aimed to estimate MIDs for all European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) scales for interpreting group-level results in brain tumor patients.METHODS: Clinical and HRQOL data from three glioma trials were used. Clinical anchors were selected for each EORTC QLQ-C30 scale, based on correlation (>0.30) and clinical plausibility of association. Changes in both HRQOL and the anchors were calculated, and for each scale and time period, patients were categorized into one of the three clinical change groups: deteriorated by one anchor category, no change, or improved by one anchor category. Mean change method and linear regression were applied to estimate MIDs for interpreting within-group change and between-group differences in change over time, respectively. Distribution-based methods were applied to generate supportive evidence.RESULTS: A total of 1687 patients were enrolled in the three trials. The retained anchors were performance status and eight Common Terminology Criteria for Adverse Events (CTCAE) scales. MIDs for interpreting within-group change ranged from 4 to 12 points for improvement and -4 to -14 points for deterioration. MIDs for between-group difference in change ranged from 4 to 9 for improvement and -4 to -16 for deterioration. Most anchor-based MIDs were closest to the 0.3 SD distribution-based estimates (range: 3-10).CONCLUSIONS: MIDs for the EORTC QLQ-C30 scales generally ranged between 4 and 11 points for both within-group mean change and between-group mean difference in change. These results can be used to interpret QLQ-C30 results from glioma trials.

AB - BACKGROUND: Minimally important differences (MIDs) allow interpretation of the clinical relevance of health-related quality of life (HRQOL) results. This study aimed to estimate MIDs for all European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) scales for interpreting group-level results in brain tumor patients.METHODS: Clinical and HRQOL data from three glioma trials were used. Clinical anchors were selected for each EORTC QLQ-C30 scale, based on correlation (>0.30) and clinical plausibility of association. Changes in both HRQOL and the anchors were calculated, and for each scale and time period, patients were categorized into one of the three clinical change groups: deteriorated by one anchor category, no change, or improved by one anchor category. Mean change method and linear regression were applied to estimate MIDs for interpreting within-group change and between-group differences in change over time, respectively. Distribution-based methods were applied to generate supportive evidence.RESULTS: A total of 1687 patients were enrolled in the three trials. The retained anchors were performance status and eight Common Terminology Criteria for Adverse Events (CTCAE) scales. MIDs for interpreting within-group change ranged from 4 to 12 points for improvement and -4 to -14 points for deterioration. MIDs for between-group difference in change ranged from 4 to 9 for improvement and -4 to -16 for deterioration. Most anchor-based MIDs were closest to the 0.3 SD distribution-based estimates (range: 3-10).CONCLUSIONS: MIDs for the EORTC QLQ-C30 scales generally ranged between 4 and 11 points for both within-group mean change and between-group mean difference in change. These results can be used to interpret QLQ-C30 results from glioma trials.

KW - Brain Neoplasms

KW - Glioma

KW - Humans

KW - Quality of Life

KW - Research Design

KW - Surveys and Questionnaires

KW - minimally important difference (MID)

KW - brain tumor

KW - clinical relevance

KW - EORTC QLQ-C30

KW - health-related quality of life (HRQOL)

UR - http://www.scopus.com/inward/record.url?scp=85112086691&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noab037

DO - 10.1093/neuonc/noab037

M3 - Journal article

C2 - 33598685

VL - 23

SP - 1327

EP - 1336

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 8

ER -

ID: 67449950